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Abstract
Epigenetic silencing is one of the mechanisms leading to inactivation of a tumor suppressor gene, either by DNA
methylation or histone modification in a promoter regulatory region. Mitogen inducible gene 6 (MIG-6), mainly known as
a negative feedback inhibitor of the epidermal growth factor receptor (EGFR) family, is a tumor suppressor gene that is
associated with many human cancers. To determine if MIG-6 is inactivated by epigenetic alteration, we identified a group of
human lung cancer and melanoma cell lines in which its expression is either low or undetectable and studied the effects of
methylation and of histone deacetylation on its expression. The DNA methyltransferase (DNMT) inhibitor 5-aza-29-
deoxycytidine (5-aza-dC) induced MIG-6 expression in melanoma cell lines but little in lung cancer lines. By contrast, the
histone deacetylase (HDAC) inhibitor trichostatin A (TSA) induced MIG-6 expression in lung cancer lines but had little effect
in melanoma lines. However, the MIG-6 promoter itself did not appear to be directly affected by either methylation or
histone deacetylation, indicating an indirect regulatory mechanism. Luciferase reporter assays revealed that a short segment
of exon 1 in the MIG-6 gene is responsible for TSA response in the lung cancer cells; thus, the MIG-6 gene can be
epigenetically silenced through an indirect mechanism without having a physical alteration in its promoter. Furthermore,
our data also suggest that MIG-6 gene expression is differentially regulated in lung cancer and melanoma.
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Introduction
Mitogen inducible gene 6 (MIG-6) (also known as gene 33,
ERRFI1,o rRALT) is an immediate early response gene that is
expressed in various tissues and plays a critical role in many patho-
physiological states [1]. Its expression can be induced by a broad
spectrum of growth factors, hormones, or stress stimuli, and it is
associated with various chronic conditions [1,2]. Studies in mice
have revealed that Mig-6 is required for skin morphogenesis and
lung development and that it plays an important role in
maintaining joint homeostasis [3,4,5].
As a cytoplasmic scaffolding adaptor, MIG-6 has several
important protein-protein interaction motifs that may mediate
interaction with signaling molecules downstream of receptor
tyrosine kinases (RTKs) [2]. One of the most prominent roles of
MIG-6 in regulating signal transduction comes from its ability to
directly interact with epidermal growth factor receptor (EGFR)
and other ErbB family members, inhibiting their phosphorylation
and downstream signaling in a negative feedback fashion [6,7,8,9].
MIG-6 can be induced by hepatocyte growth factor (HGF) and
functions as a negative feedback regulator of HGF-MET signaling
[10,11], indicating that it has broad role as a signal checkpoint for
modulating activated RTK pathways in a timely manner.
The evidence that MIG-6 is a tumor suppressor gene is
compelling. It is located in chromosome 1p36, a locus that
frequently has loss of heterozygosity in several human cancers
including lung cancer [12,13,14], melanoma [15], and breast
cancer [16]. Indeed, down-regulation or loss of MIG-6 expression
has been reported in cancers and is often associated with poor
prognosis [3,11,16,17,18,19,20,21,22,23]. MIG-6 down-regulation
in non-small cell lung cancer (NSCLC) is associated with increased
EGFR signaling and poorly differentiated cancer [21], while loss
of its expression in ErbB2-amplified breast carcinoma renders the
cancer cells more resistant to Herceptin, the neutralizing antibody
against ErbB2 [16]. In glioblastoma, MIG-6 is identified as a single
gene within the most commonly deleted region at the 1p36.23
locus, and its expression is down-regulated in 34% of glioblastoma
samples [19]. While MIG-6 down-regulation is reported in a high
percentage of papillary thyroid cancers [22], high MIG-6
expression correlates with longer survival and is associated with
favorable surgical outcomes for those patients [24]. Decreased
MIG-6 expression has also been reported in skin cancer,
endometrial cancer, and hepatocellular carcinomas [3,20,23].
Moreover, even though such events are rare, three mutations in
the MIG-6 gene have been identified in human lung cancer and
one in neuroblastoma [11,18]. Further evidence supporting MIG-6
as a tumor suppressor gene arose from mouse studies; Mig-6-
deficient mice are prone to develop epithelial hyperplasia or
tumors in organs including the lung, skin, uterus, gallbladder, and
bile duct [3,11,20].
Epigenetic alteration, one of the most well-known mechanisms
leading to inactivation of a tumor suppressor gene [25], can result
from DNA methylation or histone deacetylation in the gene’s
promoter [25]. Given that down-regulation of MIG-6 is frequently
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expression was affected by DNA methylation and histone
deacetylation. Here, we show that the MIG-6 promoter itself is
neither hypermethylated nor affected by histone deacetylation.
However, its expression is induced by the DNA methyltransferase
(DNMT) inhibitor 5-aza-29-deoxycytidine (5-aza-dC) in melano-
ma cell lines and by the histone deacetylase (HDAC) inhibitor
trichostatin A (TSA) in lung cancer lines. By dissecting its
promoter regulatory region using a luciferase reporter assay, we
identified a minimal TSA-response element in exon 1 of MIG-6
that is essential for its induction by TSA in lung cancer cells.
Results
MIG-6 expression is differentially regulated by 5-aza-dC
in melanoma cell lines and TSA in lung cancer cell lines
To determine whether MIG-6 expression was affected by
epigenetic alteration, we first identified human cancer cell lines
in which its promoter is likely affected by methylation or histone
deacetylation. As shown in Figure 1, we found four human
NSCLC cell lines (A427, H226, H522, and H596) and five
melanoma cell lines (M14, MALME-3M, SK-2, SK-MEL-28, and
UACC-257) in which MIG-6 protein was either low or undetect-
able. We then treated these cell lines with or without 5-aza-dC,
TSA, or a combination of both inhibitors.
To our surprise, we found that TSA treatment significantly
increased the amount of MIG-6 protein in the lung cancer cell
lines, but not in the melanoma lines (Figure 2A). In contrast, 5-
aza-dC treatment significantly increased the MIG-6 protein in the
melanoma cell lines, but not in the NSCLC lung cancer lines
(Figure 2B). To determine if the increase of MIG-6 protein was
regulated at transcriptional level, we performed RT-PCR analysis.
As shown in Figure 3, and consistent with protein expression,
MIG-6 mRNA expression increased with TSA treatment only in
the four lung cancer cell lines, and it increased with 5-aza-dC
treatment only in the five melanoma lines. These data strongly
suggest that the induction of MIG-6 expression by 5-aza-dC or
TSA is regulated at the transcriptional level and is differentially
regulated in the lung cancer and melanoma cells.
The MIG-6 promoter is neither hypermethylated nor
directly affected by histone deacetylation
Given that MIG-6 expression was induced by 5-aza-dC in the
melanoma lines, we asked if its promoter was hypermethylated in
those cells. We extracted genomic DNA from both lung cancer
and melanoma cell lines and examined DNA methylation in the
596-bp MIG-6 promoter regulatory region, which contains
abundant CpG sites (Figure 4). To our surprise, the lung cancer
cell lines (Figure 4A) and the melanoma cell lines (Figure 4B) were
similar in having very few methylated CpG sites in the MIG-6
promoter regulatory region, indicating that induction of MIG-6 by
5-aza-dC in melanoma was independent of DNA methylation in
its promoter. These results were confirmed by direct sequencing of
the PCR products amplified from bisulfite-treated DNAs (data not
shown).
Similarly, we asked if the MIG-6 promoter was influenced by
histone deacetylation. By chromatin immunoprecipitation assay
(ChIP), we found that TSA treatment did not increase the binding
of acetyl-histone H3 to the MIG-6 promoter in the lung cancer
lines or in the melanoma lines (Figure 5), indicating that the MIG-6
promoter was not directly affected by histone deacetylation either.
MIG-6 transcription is indirectly regulated by a factor(s)
that is affected by methylation or histone deacetylation
Because the above data suggest that MIG-6 induction is not
directly regulated, we looked for a secondary mechanism, with the
inhibitors inducing expression of a transcription factor(s) or co-
factor(s) that in turn regulates MIG-6 expression. Thus, we
examined the responses of the MIG-6 promoter regulatory region
to the inhibitors via luciferase reporter assay. A MIG-6 promoter
reporter plasmid was constructed by inserting a 1.383-kb genomic
DNA fragment (consisting of the MIG-6 promoter, its upstream
regulatory region, and the downstream exon 1 and part of intron
1) in front of a luciferase reporter gene. Testing the reporter in
both lung cancer and melanoma cell lines, we found that TSA
significantly enhanced MIG-6 promoter activity in lung cancer
cells but showed no such effect in melanoma cells (Figure 6). This
data was consistent with our prior western blot and RT-PCR
analyses. 5-aza-dC, however, appeared to have no effect on
reporter activity in either the melanoma or lung cancer lines
(Figure 6). These data indicate that while the TSA-responsive
element is within the 1.383-kb region of MIG-6, the 5-aza-dC-
responsive element is likely outside this region.
A small segment of exon 1 in MIG-6 is essential for TSA
response in lung cancer
We performed a series of deletion analyses in the 1.383-kb MIG-
6 promoter regulatory region to determine the minimal region
required for induction by TSA in lung cancer cells. Deletion from
the 59-terminus to the proximal region of the MIG-6 promoter
resulted in a decrease of the basal promoter activity, while the
response to TSA was essentially retained (Figure 7A). Deletion
Figure 1. MIG-6 protein levels in lung cancer and melanoma cell lines. Whole cell lysates were prepared from the indicated cell lines, and
MIG-6 was determined by western blot analysis using anti-Mig-6 polyclonal antibody. As a loading control, the same blot was probed with anti- b-
actin antibody.
doi:10.1371/journal.pone.0038955.g001
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resulted in complete loss of response to TSA (Figure 7B),
indicating that the TSA response element was downstream of
the MIG-6 promoter. Further deletion analyses revealed a small
segment in the exon 1 starting from the transcriptional initiation
site that was essential for TSA responsiveness (Figure 7C). As
summarized in Figure 7D, the minimal TSA response element is
within the first 50 nucleotides of exon 1, with the distal 20-
nucleotide segment showing the highest activity.
We speculated that there exists a critical transcription factor
binding motif in the minimal TSA response element. We
performed mutation analyses of the 50-nucleotide segment to
pinpoint potential transcription factor binding motif(s) (Figure 8A).
Compared with the wild-type P(-76/+50) reporter, mutation in the
m4 and m5 elements resulted in a significant decrease of reporter
activity in response to TSA, while mutation in other elements had
lesser effect (Figure 8B). This result agrees with the deletion
analyses, as the m4 and m5 elements are within the distal 20-
nucleotide segment that, when deleted, resulted in a steep drop-off
in TSA response. We generated another mutant reporter m11 in
which half of the sequences in both m4 and m5 were mutated
(Figure 8A). We found that the m11 mutant had a much greater
reduction in TSA response (Figure 8C), indicating that those
sequences are essential for the binding of a yet to be identified
transcription factor which regulates MIG-6 gene expression
induced by TSA in the lung cancer.
Figure 2. MIG-6 protein is differentially induced by 5-aza-dC
and TSA in lung cancer and melanoma cell lines. Whole cell
lysates were extracted from the cells treated with or without 5-aza-dC
(10 mM) and/or TSA (1 mM), and western blot analyses were performed
to detect MIG-6 protein. b-actin was used as an internal control. (A)
MIG-6 protein was induced by TSA but not by 5-aza-dC in the lung
cancer lines. (B) 5-Aza-dC, but not TSA, induced MIG-6 in the melanoma
cell lines.
doi:10.1371/journal.pone.0038955.g002
Figure 3. Induction of MIG-6 expression by 5-aza-dC and TSA is
regulated at transcriptional level. Total RNAs were isolated from
cells treated with or without 5-aza-dC (10 mM) and/or TSA (1 mM), and
MIG-6 expression was determined by RT-PCR analyses. GAPDH
expression was used as an internal control. (A) TSA increased MIG-6
mRNA in the four lung cancer cell lines. (B) MIG-6 mRNA in the five
melanoma cell lines was increased by 5-aza-dC.
doi:10.1371/journal.pone.0038955.g003
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38955Figure 4. The MIG-6 promoter is hypomethylated in lung cancer and melanoma cell lines. The MIG-6 promoter was amplified from
bisulfite-converted DNA and cloned into a TOPO TA-cloning vector. The status of MIG-6 promoter methylation in (A) lung cancer cell lines and (B)
melanoma cell lines was evaluated by sequencing 10 randomly picked colonies from each line for methylated cytosine residues. Each red bar
represents a CpG site. The open ovals indicate unmethylated CpG sites and the solid ovals indicate methylated sites. EBC-1 cell line was used as
a negative control to show the basal methylation status of MIG-6 promoter.
doi:10.1371/journal.pone.0038955.g004
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in lung cancer and melanoma cells
We next asked whether there were other genes differentially
regulated by 5-aza-dC and TSA in lung cancer and melanoma
cells. We performed DNA microarray analyses on samples derived
from A427 lung cancer and M14 melanoma cells treated with 5-
aza-dC and/or TSA. Figure 9A shows the genes displaying an
expression pattern similar to that of MIG-6 (which is indicated as
ERRFI1 in the heat-map) in response to either 5-aza-dC or TSA
treatment (Figure 9A). Another group of genes appeared to be
down-regulated, the opposite of MIG-6 expression (Figure 9B).
Among the up-regulated genes were those coding for transcrip-
tion factors such as EGR1 and STAT1, the MIG-6-inducible gene
HBEGF, and genes coding for histone proteins (Figure 9A). Even
though those genes were differentially expressed in A427 and M14
cells (Figure 9A), further analyses revealed that EGR1 (but not
several other genes we examined) displayed an expression pattern
similar to that of MIG-6 across the four lung cancer cell lines and
five melanoma lines (Figure 10). Thus, MIG-6 was not the only
gene differentially regulated in the lung cancer and melanoma
cells. Perhaps there are tissue-specific factors (either transcription
factors or transcription factor co-activators/co-repressors) that
respond differently to 5-aza-dC and TSA, leading to differential
induction of MIG-6 and EGR1 in lung cancer and melanoma cells.
Discussion
MIG-6, a tumor suppressor gene, has been found down-
regulated in many human cancers. To determine if down-
regulation of MIG-6 expression was affected by epigenetic
modification in its promoter, we treated lung cancer and
melanoma cell lines with inhibitors of methylation and histone
deacetylation and then determined how those inhibitors influenced
MIG-6 expression. Intriguingly, we found that DNMT inhibitor 5-
aza-dC specifically induced MIG-6 expression in melanoma cells
but not in lung cancer cells, while the HDAC inhibitor TSA
induced the reverse pattern (Figure 2 and 3). Despite both
inductions being regulated at transcriptional level, we were
surprised to find that the MIG-6 promoter was neither hyper-
methylated nor directly affected by histone deacetylation (Figure 4
and 5), indicating that an indirect mechanism might be responsible
for differential induction. In fact, 5-aza-dC has also been reported
to induce the expression of several other genes whose promoters
are not directly affected by methylation in leukemia cells [26],
suggesting that 5-aza-dC might have a broader influence on
regulating gene expression via a methylation-independent manner.
Many DNMT inhibitors and HDAC inhibitors are currently in
clinical trials for their anti-cancer properties [27,28,29]. Even
though most of these epigenetic drugs are still in early de-
velopment and the prospects for them to be used clinically for
Figure 5. The MIG-6 promoter is not affected by histone deacetylation. The cells were treated with or without TSA (1 mM) for 24 h, and a ChIP
assay was performed using anti-acetyl histone H3 antibody. As a negative control, normal rabbit serum was used for immunoprecipitation. The DNA
fragments cross-linked and co-immunoprecipitated with the acetylated histone H3 were purified and used for PCR amplification of the promoters of
MIG-6 and GAPDH. EBC-1 cell line was used as a negative control to show the basal histone deacetylation status of MIG-6 promoter.
doi:10.1371/journal.pone.0038955.g005
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depend on our understanding of how they work and what
outcomes might be expected. 5-Aza-dC and TSA are viewed as
potent and specific inhibitors for methylation and histone
deacetylation, respectively [27,28,30], and they have been widely
used for investigating epigenetic alteration of many tumor
suppressor genes. These inhibitors usually cause global changes
in gene expression by remodeling chromatin via directly convert-
ing methylated DNA to unmethylated DNA or unacetylated
histones to the acetylated state, thereby allowing easy access of the
transcription machinery to gene promoters. However, some
inhibitors might be doing more, and their anti-cancer properties
could be much more complicated. For instance, many non-histone
cellular proteins such as transcription factors are also substrates of
HDAC, and their transcriptional activities could be affected by the
HDAC inhibitor TSA as well [29].
Most tumor suppressor genes are epigenetically silenced by
either DNA methylation and/or histone deacetylation in their
promoters [25]. To our knowledge, there is no report showing that
the expression of such genes can be differentially regulated by
inhibitors of methylation or histone deacetylation in a cancer-
specific fashion without having epigenetic modifications in the
promoter. The regulation of MIG-6 by these inhibitors, as we show
here, unveils a novel mechanism by which a tumor suppressor
gene can be epigenetically silenced in an indirect and tissue-
specific manner. Our luciferase reporter assay results indicated
that the regulation of MIG-6 expression in melanoma and in lung
cancer was most likely mediated by different factors. We have
identified a minimal TSA response element in exon 1 of MIG-6
proximal to its promoter (Figure 7 and 8), while location of the 5-
aza-dC response element is still uncertain (Figure 6).
We speculate that the TSA response element in the MIG-6 gene
is most likely regulated by a factor whose expression is affected by
histone deacetylation in its promoter or whose protein activity is
directly regulated by acetylation/deacetylation (Figure 11A). This
factor would be activated in lung cancer cells upon TSA
treatment, but not in melanoma cells. Within the minimal TSA-
response element that we identified in MIG-6 gene exon 1
(Figure 7), there are putative DNA binding sequences for the
transcription factor activator protein-2 (TFAP2), which has five
family members and binds to the consensus sequence 59-
GCCNNNGGC-39 [31,32]. When the putative TFAP2 binding
sites were mutated, we observed a significant drop in TSA-
responsiveness (Figure 8), indicating that those sequences are
crucial for TSA-mediated regulation. It will be interesting to see if
TFAP2 or other factor(s) binds to those sequences and regulates
MIG-6 gene expression. As for 5-aza-dC, its response element is
likely outside the tested 1.383-kb MIG-6 promoter regulatory
region (Figure 6); that is, it is either directly affected by
methylation in its DNA sequences or is indirectly mediated by
another transcriptional regulator whose promoter is modified by
methylation in melanoma cells (Figure 11B). Extensive studies will
be required to determine what those factors are and how they
control MIG-6 expression.
Figure 6. Determining 5-aza-dC- and TSA-response elements in the MIG-6 promoter regulatory region. Lung cancer and melanoma cell
lines were transiently transfected with luciferase reporter plasmids, either pGL3-Basic or pGL3-P(21076/+307), followed by treatment with or without
5-aza-dC or TSA. The pU6B-Renilla reporter was co-transfected for normalization. Each assay was performed in triplicate. The error bars represent
standard deviation. The student t-test p value indicates a statistically significant difference between the mock-treated and the TSA-treated samples.
doi:10.1371/journal.pone.0038955.g006
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methylation and histone deacetylation is not unique to MIG-6.
Other genes such as EGR1 [33] are also differentially regulated in
lung cancer and melanoma cells by those inhibitors (see Figures 9
and 10). It remains to be determined whether–like the MIG-6
promoter–the EGR1 promoter is neither hypermethylated nor
affected by histone deacetylation in those cells. If these character-
Figure 7. Mapping the TSA-response element in the MIG-6 promoter regulatory region by deletion analyses. (A–C) Different lengths of
the MIG-6 promoter regulatory region were inserted into the pGL3 vector. The luciferase reporter assay was performed in A427 lung cancer cells
transiently transfected with pGL3-Basic or the indicated reporter carrying MIG-6 promoter element. The cells were then treated with or without 5-aza-
dC or TSA. The pU6B-Renilla reporter was co-transfected for normalization. Each assay was performed in triplicate. The error bars represent standard
deviation. (D) Schematic representation of the TSA-response element in the MIG-6 promoter regulatory region. The arrow indicates the transcription
starting site; the red box indicates exon 1. Shaded in green is the 50-bp element in exon 1 that is most likely responsible for TSA response in lung
cancer cells, which we designated as the minimal TSA-response element.
doi:10.1371/journal.pone.0038955.g007
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if they are regulated by same factor(s) or via different mechanisms.
We report here that MIG-6 expression is differentially regulated
by inhibitors of methylation and histone deacetylation in lung
cancer and melanoma cells without physical epigenetic alterations
in its promoter. MIG-6 (and possibly EGR1) may serve as valuable
biomarkers for determining the sensitivity/suitability of a cancer




The human lung cancer cell lines A427, NCI-H292, NCI-
H2122, NCI-H596, and SK-MES-1 were obtained from Amer-
ican Type Culture Collection (Manassas, VA). EBC-1 was from
the Health Science Research Resources Bank (Tokyo, Japan).
NCI-H226 and NCI-H522 were obtained from NCI-60 cell lines
(NCI-Frederick). They were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomy-
cin. The human melanoma cell lines A375, C8161R, MALME-
3M, M14, SK-2, SK-MEL-28, SK-MEL-103, SK-MEL-147,
UACC-62, and UACC-257 were kindly provided by Dr. Matthew
VanBrocklin (Nevada Cancer Institute, Las Vegas, NV) [34] and
maintained in RPMI supplemented with 5% FBS and 1%
penicillin/streptomycin.
Plasmids
A series of DNA fragments derived from the MIG-6 promoter
regulatory region were inserted into BglII and KpnI sites in the
promoter-less luciferase reporter pGL3-Basic (Promega, Madison,
WI) to create the plasmids pGL3-P(21076/+307),–P(2533/
+307),–P(2106/+307),–P(276/+307),–P(276/+255),–P(276/
Figure 8. Dissecting the minimal TSA-response element in MIG-6 by mutational analysis. (A) The sequences of P(276/+50) that contain
the MIG-6 promoter and the minimal TSA-response element are shown. For each mutant reporter construct (m3-m11), the underlined sequence was
mutated to GAATTC. (B and C) A luciferase reporter assay was performed in A427 lung cancer cells by transiently transfecting the indicated reporter
plasmid with or without TSA treatment. The error bars represent standard deviation and all assays were performed in triplicate.
doi:10.1371/journal.pone.0038955.g008
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+31),–P(276/+20),–P(276/+10), and–P(276/21). All inserted
fragments were amplified by polymerase chain reaction (PCR)
using Pfu turbo DNA polymerase (Stratagene, La Jolla, CA), and
the resulting plasmids were sequenced to confirm the accuracy of
the inserts.
All pGL3-P(276/+50) mutant reporters were created using
a QuikChange Site-Directed Mutagenesis Kit (Stratagene) by
mutating each of six original nucleotides into an EcoRI restriction
enzyme site (GAATTC), which was confirmed by sequencing. The
primers used for creating each mutant reporter are as follows: for
pGL3-P(276/+50)m3, 59-TAGCGGGAGCGCGAGAATT-
CAAGAGGCGCCTGCG-39 (sense) and 59-
CGCAGGCGCCTCTTGAATTCTCGCGCTCCCGCTA-39
(antisense); for–P(276/+50)m4, 59-GAGCGCGAGCCAGCA-
GAATTCGCCTGCGCAGATCT-39 (sense) and 59-
AGATCTGCGCAGGCGAATTCTGCTGGCTCGCGCTC-39
(antisense); for–P(276/+50)m5, 59-AGCCAGCAAGAGGC-
GAATTCGCAGATCTGCGATCT-39 (sense) and 59-
AGATCGCAGATCTGCGAATTCGCCTCTTGCTGGCT-39
Figure 9. MIG-6 is not the only gene differentially regulated by 5-aza-dC and TSA in lung cancer and melanoma cells. Microarray
analyses were performed on RNA samples from A427 lung cancer cells and M14 melanoma cells treated with or without 5-aza-dC (10 mM) and/or TSA
(1 mM). The heat maps show (A) the genes whose expression pattern was similar to that of MIG-6, and (B) the genes whose expression was down-
regulated by the treatment, in contrast to MIG-6 expression. The MIG-6 gene is indicated with an asterisk and is shown as the alternative symbol,
ERRFI1.
doi:10.1371/journal.pone.0038955.g009
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39 (sense) and 59-CTCCCGCTAGCACTCGAATTCGCACCG-
GACCGCCG-39 (antisense); for–P(276/+50)m8, 59-
CCGGTGCGAGGCAGAATTCTAGCGGGAGCGCGA-39
(sense) and 59-TCGCGCTCCCGCTAGAATTCTGCCTCG-
CACCGG-39 (antisense); for–P(276/+50)m9, 59-GAGGCA-
GAGTGCTAGAATTCGCGCGAGCCAGCAAG-39 (sense)
and 59-CTTGCTGGCTCGCGCGAATTCTAG-
CACTCTGCCTC-39 (antisense); for–P(276/+50)m10, 59-
GAGTGCTAGCGGGAGAATTCGCCAGCAAGAGGCGC-39
(sense) and 59-GCGCCTCTTGCTGGCGAATTCTCCCGC-
TAGCACTC-39 (antisense); and for–P(276/+50)m11, 59-
GCGAGCCAGCAAGAGAATTCTGCGCAGATCTGCG-39
(sense) and 59-CGCAGATCTGCGCA-
GAATTCTCTTGCTGGCTCGC-39 (antisense). The underline
indicates the EcoRI site for each mutant.
Western Blot Analysis
To prepare protein lysates, cells were treated with or without 5-
aza-dC (10 mM) for 3 d or TSA (1 mM) for 1 d in complete growth
medium. For the combination of the two, cells were treated with 5-
aza-dC for 2 d, followed by TSA treatment for 1 d. Whole cell
lysates were extracted in RIPA buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1% NP 40, 0.5% deoxycholate, 0.1% SDS, 1 mM
EDTA, 50 mM NaF, 1 mM sodium orthovanadate, and Com-
plete Proteinase Inhibitor Cocktail tablets), quantified using a DC
Protein Assay Kit (Bio-Rad, Hercules, CA), and adjusted with
equal volume of 26Laemmli Sample Buffer (Sigma, Saint Louis,
MO). The protein was run in a 10% Tris-glycine gel (Invitrogen,
Grand Island, NY), transferred onto a PVDF membrane, and
probed with anti-MIG-6 [11] or anti-b-actin antibody (Sigma).
RNA Preparation and RT-PCR Analysis
Using TRIzol reagent (Invitrogen), total RNA was isolated from
each cell line treated with 5-aza-dC and/or TSA and from
controls, as detailed above. For reverse transcription (RT)-PCR,
first-strand cDNA was first synthesized from 1 mg RNA using
SuperScript II reverse transcriptase (Invitrogen), followed by PCR
amplification using 5% cDNA for each reaction. Following are the
primers used for amplification of each gene: for MIG-6,5 9-
ATGTCAATAGCAGGAGTTGCTG-39 (sense) and 59-
GTCTAAGGAGAAACCACATAGG-39 (antisense); for GAPDH,
59-AACGGATTTGGTCGTATTGGGC-39 (sense) and 59-
GCTTCACCACCTTCTTGATGTC-39 (antisense); and for
EGR1,5 9-AACTGTGTCCCCTGCAGCTCCA-39 (sense) and
59-CCACAAGGTGTTGCCACTGTTG-39 (antisense).
Bisulfite DNA Sequencing
Genomic DNAs isolated from each cell line were subjected to
sodium bisulfite conversion of unmethylated cytosine in DNA
using EpiTect Bisulfite Kit (QIAGEN, Valencia, CA) according to
the manufacturer’s protocol. Bisulfite-treated DNAs were then
used for nested PCR using following primers: 59-GGAGAG-
GAAAAAATATATAATTTTGTT-39 (forward primer p1) and
59-TCTCCCTCCATCCCAAAAACTC-39 (reverse primer p5)
for the first round of PCR, and for the second round, forward
primer p1 and 59-TAACCCTCCCCACCCCCTCAAC-39 (re-
verse primer p4). The second round PCR products (596 bp) were
then cloned into the TOPO TA Cloning vector (Invitrogen). For
each cell line, 10 different colonies were picked and the inserts
were sequenced. Direct sequencing of the second round PCR
products was also performed. The MethPrimer program (www.
urogene.org/methprimer) was used for analyzing CpG islands in
the MIG-6 gene.
Chromatin Immunoprecipitation (ChIP) Assay
The ChIP assay was performed using a Chromatin Immuno-
precipitation Assay Kit (Upstate, Lake Placid, NY) according to
the manufacturer’s instructions. Briefly, cells were treated with or
without TSA (1 mM) for overnight, and then histones in the cells
were cross-linked to DNA by 1% formaldehyde treatment for
10 min. After crosslinking, cells were collected, resuspended in
SDS lysis buffer, and sonicated to shear the DNA. The lysates
were centrifuged to clear debris, and the supernatants were
collected and diluted with 10-fold ChIP Dilution Buffer containing
Figure 10. EGR1 displays an expression pattern similar to that
of MIG-6 in lung cancer and melanoma cell lines upon 5-aza-dC
and TSA treatment. The expression of EGR1 was determined by RT-
PCR. (A) TSA induced EGR1 expression in the NCI-H226, NCI-H522, NCI-
H596, and A427 lung cancer cell lines. (B) 5-Aza-dC induced EGR1
expression in the M14, MALME-3M, SK-2, SK-MEL-28, and UACC-257
melanoma cell lines. GAPDH expression was used as an internal control
(see Figure 3).
doi:10.1371/journal.pone.0038955.g010
Epigenetic Regulation of MIG-6 Gene Expression
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38955protease inhibitor cocktail (Roche, Indianapolis, IN). The diluted
supernatants were then incubated with either anti-acetyl histone
H3 antibody (Upstate) or normal rabbit serum (as negative control)
overnight at 4uC, followed by a 1 h incubation with Protein A
agarose/salmon sperm DNA for immunoprecipitation. After
extensive washing, the precipitated antibody/histone/DNA com-
plex was eluted in freshly prepared elution buffer (1% SDS, 0.1 M
NaHCO3), and the histone-DNA crosslinks were reversed by
heating at 65uC for 4 h. Precipitated DNAs were recovered by
phenol/chloroform extraction and ethanol precipitation and then
stored at 220uC until used for PCR. Primers used for PCR were
as follows: for the MIG-6 gene promoter, 59-
AGACGCCTCTCCGGGAGAC-39 (forward) and 59-
ATAGGCCGCCGGGCCGTGA-39 (reverse); and for the
GAPDH gene promoter, 59-TCGGTGCGTGCCCAGTT-
GAACC-39 (forward) and 59-ATGCGGCTGACTGTCGAA-
CAGG-39 (reverse).
Microarray Analysis
Total RNA was isolated from A427 and M14 cells treated with
5-aza-dC and/or TSA and from controls, as described above.
Agilent 44K One-Color Microarrays (Agilent, Santa Clara, CA)
were used for detection and analyses of gene expression.
Luciferase Reporter Assay
The day before transfection, 5610
4 cells were seeded in each
well of a 96-well plate. The firefly luciferase reporter plasmid
pGL3-luc or its derivative (100 ng) was co-transfected with pU6B-
Renilla reporter (5 ng) using Lipofectamine 2000 (Invitrogen)
overnight. The cells were then treated with 5-aza-dC (10 mM)
for 2 d or TSA (1 mM) for 1 d. The luciferase reporter activities
were assayed using the Dual-Luciferase Reporter Assay System
(Promega) and measured using an EnVision 2104 Multilabel
Reader (PerkinElmer, Waltham, MA). The firefly luciferase
activities were normalized for analyses using Renilla luciferase
activities.
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